Absci is trading 6.13% lower at $9.64, with no verified company-specific announcement identified to explain the October 7 decline.
- Biotech shares fell 3.39% as rising yields and oil prices, geopolitical supply concerns, and caution ahead of Federal Reserve minutes weighed on markets.
- The broader market was also lower, supporting a macro and sector explanation rather than a confirmed company catalyst.
- The latest identified Absci-specific news was not a new October 7 announcement; its connection to this move is unverified.